XML 21 R5.htm IDEA: XBRL DOCUMENT v3.5.0.1
Statement of Stockholders' Equity - USD ($)
Total
Common Stock [Member]
Common Stock [Member]
Vyrix Pharmaceuticals Inc [Member]
Parent's Equity [Member]
Parent's Equity [Member]
Vyrix Pharmaceuticals Inc [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Vyrix Pharmaceuticals Inc [Member]
Ampio Stock Subscription [Member]
Accumulated Deficit [Member]
Balance at Jun. 30, 2013 $ 9,811,197 $ 544   $ 10,471,515   $ 4,418,385     $ (5,079,247)
Balance (in shares) at Jun. 30, 2013   5,437,158              
Investment from Ampio in Vyrix 637,210     $ 637,210          
Issuance of common stock in exchange for Vyrix Acquired Assets     $ 246   $ (11,108,725)   $ 11,108,479    
Issuance of common stock in exchange for Vyrix Acquired Assets (in shares)     2,464,268            
Stock-based compensation $ 499,690         499,690      
Stock-based compensation (in shares) 0                
Net loss $ (5,578,690)               (5,578,690)
Balance at Jun. 30, 2014 5,369,407 $ 790       16,026,554     (10,657,937)
Balance (in shares) at Jun. 30, 2014   7,901,426              
Ampio stock subscription (aunaudited)   $ 216       9,999,784   $ (10,000,000)  
Ampio stock subscription (in shares)   2,164,448              
Issuance of common stock to Ampio in exchange for Aytu debt 12,000,000 $ 260       11,999,740      
Issuance of common stock to Ampio in exchange for Aytu debt (in shares)   2,597,339              
Stock subscription 5,000,000             5,000,000  
Liabilities paid pursuant to the merger (20,013)         (20,013)      
Luoxis options paid-out pursuant to the merger (27,476)         (27,476)      
Reverse merger   $ 160       (160)      
Reverse merger (in shares)   1,596,468              
Stock-based compensation 1,017,938         1,017,938      
Net loss (7,723,404)               (7,723,404)
Balance at Jun. 30, 2015 15,616,452 $ 1,426       38,996,367   (5,000,000) (18,381,341)
Balance (in shares) at Jun. 30, 2015   14,259,681              
Adjustment for rounding of shares due to conversion (unaudited) 0 $ 0       0   0 0
Adjustment for rounding of shares due to conversion (unaudited) (in shares)   12              
Ampio stock subscription (aunaudited) 5,000,000 $ 0       0   5,000,000 0
Stock subscription 200,000 $ 31       199,969   0 0
Stock subscription (in shares)   307,692              
Conversion of convertible promissory notes to common stock, net of conversion costs 8,997,957 $ 788       8,997,169   0 0
Conversion of convertible promissory notes to common stock, net of conversion costs (in shares)   7,879,096              
Issuance of warrants related to the convertible promissory notes (unaudited) 87,000 $ 0       86,781   0 0
Stock-based compensation 547,109 $ 0       547,109   0 0
Stock-based compensation (in shares)   0              
Net loss (12,882,626) $ 0       0   0 (12,882,626)
Balance at Mar. 31, 2016 $ 17,565,673 $ 2,245       $ 48,827,395   $ 0 $ (31,263,967)
Balance (in shares) at Mar. 31, 2016   22,446,481